Last $1.28 USD
Change Today 0.00 / 0.00%
Volume 39.8K
As of 12:00 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONCY) Snapshot

Open
$1.29
Previous Close
$1.28
Day High
$1.31
Day Low
$1.27
52 Week High
09/9/13 - $3.50
52 Week Low
05/9/14 - $1.20
Market Cap
112.0M
Average Volume 10 Days
132.3K
EPS TTM
--
Shares Outstanding
87.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONCY)

oncolytics biotech inc (ONCY) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONCY) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONCY) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

oncolytics biotech inc (ONCY) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: C$530.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: C$280.0K
Chief Operating Officer and Director
Total Annual Compensation: C$365.0K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: C$331.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $271.2K
Compensation as of Fiscal Year 2013.

oncolytics biotech inc (ONCY) Key Developments

Oncolytics Biotech Seeks Acquisitions

Oncolytics Biotech Inc. (TSX:ONC) has filed a follow-on equity offering in the amount of $11.80 million. Oncolytics Biotech siad, "We intend to use approximately $11.7 million of the estimated net proceeds from this offering for working capital and other general corporate purposes. Working capital and other general corporate purposes may include funding ongoing operations and/or capital requirements, discretionary capital programs and potential future acquisitions."

Oncolytics Biotech Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Oncolytics Biotech Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported operating loss of $4,764,870 against $5,125,049 a year ago. Loss before income taxes was $4,714,617 against $5,019,681 a year ago. Net loss was $4,718,163 or $0.05 per diluted share against $5,019,681 or $0.06 per diluted share a year ago. Cash used in operating activities was $5,780,235 against $5,109,598 a year ago. Acquisition of property and equipment was $1,239 against $132,164 a year ago. For the six months, the company reported operating loss of $10,334,458 against $11,806,844 a year ago. Loss before income taxes was $10,196,218 against $11,626,517 a year ago. Net loss was $10,203,614 or $0.12 per diluted share against $11,626,517 or $0.14 per diluted share a year ago. Cash used in operating activities was $11,944,313 against $13,519,820 a year ago. Acquisition of property and equipment was $17,219 against $147,302 a year ago.

Oncolytics Biotech Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 08:35 AM

Oncolytics Biotech Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 08:35 AM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Bradley G. Thompson, Executive Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCY:US $1.28 USD 0.00

ONCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCY.
View Industry Companies
 

Industry Analysis

ONCY

Industry Average

Valuation ONCY Industry Range
No financial data is available for ONCY.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.